Common use of Publications and Presentations Clause in Contracts

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by and written approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Notwithstanding the foregoing, in the event that a Party reasonably requests a response by the other Party in less than * (*) days, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings and (b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the research and Development activities hereunder. Accordingly, during the Research Term neither Party shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in such publications. For clarity, nothing in this Section 13.5 shall limit Dynavax’s right to publish or present, during the Research Term, the results of any studies carried out by or on behalf of Dynavax prior to the Effective Date. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by and written approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s any proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verballyincluding verbal presentations) that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Development Program Agreement at least [ * (*) ] days prior to its their intended presentation or submission for publication, publication and such submitting Party agrees, upon written request from the other Party given within such * (*) day periodrequest, not to submit any such abstract or manuscript for publication or to make such presentation until the other Party is given up to a reasonable period of time (resulting in a total of no more than [ * (*) ] days from the date provision of such written request abstracts, manuscripts or presentation by one Party to seek appropriate the other for review until such Party’s submission of such abstracts, manuscripts or presentation for publication) to secure patent protection for any material in such publication or presentation that which it reasonably believes may to be patentable. Notwithstanding the foregoing, in the event Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to review and decide whether to delay the publication and filing of patent applications under certain circumstances. Neither Party reasonably requests a response by the other Party in less than * (*) days, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its publish or present Confidential Information that of the other Party which is disclosed in subject to Section 13.1. With respect to any such proposed publication or presentation be deleted prior made by AstraZeneca pursuant to such publication or presentationthis Section 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Dynavax Technology in the Dynavax ISS, Collaboration ISS, CDs, Product and/or any Combination Product. In any permitted publication or presentation by a Party[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, the other Party’s contribution shall be duly recognizedMARKED BY BRACKETS, and co-authorship shall be determined in accordance with customary standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journalsHAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, presentation at scientific conferences and meetings and (b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Development Program in accordance with its internal publication guidelinesAS AMENDED.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the research and Development activities hereunder. Accordingly, during the Research Term neither Party shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in such publications. For clarity, nothing in this Section 13.5 shall limit Dynavax’s right to publish or present, during the Research Term, the results of any studies carried out by or on behalf of Dynavax prior to the Effective Date. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by and written approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s any proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verballyincluding verbal presentations) that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Development Program Agreement at least [ * (*) ] days prior to its their intended presentation or submission for publication, publication and such submitting Party agrees, upon written request from the other Party given within such * (*) day periodrequest, not to submit any such abstract or manuscript for publication or to make such presentation until the other Party is given up to a reasonable period of time (resulting in a total of no more than [ * (*) ] days from the date provision of such written request abstracts, manuscripts or presentation by one Party to seek appropriate the other for review until [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. such Party’s submission of such abstracts, manuscripts or presentation for publication) to secure patent protection for any material in such publication or presentation that which it reasonably believes may to be patentable. Notwithstanding the foregoing, in the event Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to review and decide whether to delay the publication and filing of patent applications under certain circumstances. Neither Party reasonably requests a response by the other Party in less than * (*) days, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its publish or present Confidential Information that of the other Party which is disclosed in subject to Section 13.1. With respect to any such proposed publication or presentation be deleted prior made by AstraZeneca pursuant to such publication or presentation. In this Section 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Dynavax Technology in the Dynavax ISS, Collaboration ISS, CDs, Product and/or any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings and (b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Development Program in accordance with its internal publication guidelinesCombination Product.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored In the event “[***]” wishes to prevent any adverse effect from premature make a publication or dissemination of results public presentation related to this Agreement, “[***]” shall deliver to Intec Pharma a copy of the activities hereunder. Each proposed written publication or an outline of the proposed oral presentation at least thirty (30) days (or, in the case of consulting or Third Party agrees thatresearch agreements, except such shorter period as required by Applicable Laws, it shall not publish the consulting or present, or permit to be published or presented, the results of the Development Program without the prior review by and written approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verballyresearch agreement) that relate to the Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentablepresentation. Notwithstanding the foregoing, in the event that a Party reasonably requests a response by the other Party in less than * (*) days, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also Intec Pharma shall have the right to require that delay such proposed publication or presentation for up to sixty (60) days (or, in the case of consulting or Third Party research agreements, such shorter period as required by the consulting or other research agreement) in order to file patent applications protecting Intec Pharma’s rights in any information included in such proposed publication or presentation to the extent such filings are consistent with Section 7.1.1 (Intec Pharma Prosecution Rights), and Intec Pharma shall have the right to request the removal or redaction of any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such presentation. Intec Pharma shall not make any publication or presentation. In public presentation related to this Agreement or any permitted publication activities hereunder, except for such publications or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. Each Party public presentations that (a) expressly acknowledges that relate solely to the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings general applicability of the Accordion Pill System and (b) agrees that it shall do not unreasonably withholddirectly or indirectly identify “[***]”, condition the Product, the Agreement “[***]”Technology or delay its consent to any request by specific activities conducted under the other Party to publish results of the Development Program in accordance with its internal publication guidelinesResearch Plan. NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees thatThe Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, except as required by Applicable Lawsincluding publications and presentations relating to Biomarkers, it Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by and written approval of the other Party. Each Party shall provide report to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentableJDC. Notwithstanding the foregoing, in the event that a Party reasonably requests a response by the other Party in less than * (*i) daysexcept for disclosures permitted pursuant to Section 5.2, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by each either Party, the same abstracts, manuscripts its employees or presentations do not have consultants wishing to be provided again make a publication shall deliver to the other Party for review for a later copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with such consultant) prior to submission for publication. Each publication or presentation, (ii) the reviewing Party also shall have the right to require that a delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship ownership shall be determined in accordance with customary standards. Each In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (a60) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results and ninety (90) day periods set forth in scientific journals, presentation at scientific conferences and meetings clauses (i) and (bii) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Development Program in accordance with its internal publication guidelinesabove.

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees thatThe Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, except as required by Applicable Lawsincluding publications and presentations relating to Biomarkers, it Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by and written approval of the other Party. Each Party shall provide report to the other Party JDC until such time as the opportunity JSC determines that the Publication Committee shall report to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Development Program at least * (*) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such * (*) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to * (*) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentablea different entity. Notwithstanding the foregoing, in the event that a Party reasonably requests a response by the other Party in less than * (*i) daysexcept for disclosures permitted pursuant to Section 5.2, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by each either Party, the same abstracts, manuscripts its employees or presentations do not have consultants wishing to be provided again make a publication shall deliver to the other Party for review for a later copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required by the consulting or other agreement with such consultant) prior to submission for publication. Each publication or presentation, (ii) the reviewing Party also shall have the right to require that a delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship ownership shall be determined in accordance with customary standards. Each In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (a60) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results and ninety (90) day periods set forth in scientific journals, presentation at scientific conferences and meetings clauses (i) and (bii) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by above. Portions of this Exhibit were omitted and have been filed separately with the other Party to publish results Secretary of the Development Program in accordance with its internal publication guidelinesCommission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.